november AG and Swedish MediRox AB intensify cooperation

16-Oct-2001

The Erlangen/Germany-based biotechnology company november AG and the Swedish medical technology corporation MediRox AB intensify their collaboration, which was initiated in January 2001. This most recent agreement between the two companies grants exclusive rights to MediRox for further development and marketing of novi quick®, a system developed by november AG for self-control of anticoagulation treatment. In return, november AG will receive a percentage of sales as well as a significant share of the Swedish hemostasis specialist. he novi quick® technology allows physicians and patients easy and safe surveillance of the treatment, for instance after the implantation of artificial heart valves, after thrombosis or as stroke prophylaxis. MediRox already is exclusive supplier of quality reagents, and a strategic partner for R&D and sales of this system. The Swedish medical technology company plans to further develop and market the novi quick® technology in various application systems. The broad distribution network of MediRox in Scandinavia through its wholly owned subsidiary ILS laboratories Scandinavia and its close ties to hospitals will serve as an excellent foundation. For MediRox, the agreement allows a broader application of its proprietary technology in the area of circulatory disorders with increased focus on global diagnostic procedures and identification of drug candidates. For november AG (WKN 676290), listed at the "Neuer Markt" segment of the German stock-exchange, the exclusive licensing of the novi quick® technology to MediRox AB signifies another important step in focussing on its core business of molecular diagnosis and molecular therapy, a broadening of the cooperation on an international basis and a contribution to secure future benefits in the field of anticoagulation.

https://www.chemeurope.com/en/news/5468/november-ag-and-swedish-medirox-ab-intensify-cooperation.html